▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / REGN

REGN — REGENERON PHARMACEUTICALS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 872589 ·
Last close
$618.03
Market Cap
$63.67B
52W High
$780.04
52W Low
$591.52
ADV30
1,234,914
Next earnings
2026-07-30
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 3,605,400,000 2,936,000,000 744,800,000 727,200,000 40,868,800,000 2,962,600,000 9,445,200,000
Dec 2025 3,884,300,000 3,299,700,000 898,600,000 844,600,000 40,558,700,000 3,118,100,000 9,301,800,000
Sep 2025 3,754,300,000 3,232,700,000 1,109,900,000 1,460,000,000 40,169,400,000 2,506,400,000 9,211,600,000
Jun 2025 3,675,600,000 3,145,400,000 1,079,500,000 1,391,600,000 38,219,200,000 1,995,800,000 8,280,300,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$5,012,700,000
Investing CF
$-1,705,500,000
Financing CF
$-3,428,400,000
CapEx
$-1,221,700,000
Dividends Paid
$-374,300,000
Buybacks
$-3,792,500,000
EPS Diluted TTM
$41.04
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$36,423,800,000
Inventory
$3,103,600,000
Receivables
$5,731,000,000
ST Investments
$5,791,100,000
EBIT TTM
$5,204,900,000
Pretax Income TTM
$5,156,900,000
Interest Exp TTM
$48,000,000
Analysts
28

Yahoo Snapshot (yfinance, live)

Total Revenue
$14,919,600,128
EBITDA
$4,382,799,872
Free Cash Flow
$3,273,349,888
Enterprise Value
$56,830,275,584
Total Cash
$8,753,699,840
Total Debt
$2,706,200,064
Shares Out
103,021,886
Trailing EPS
$40.98
Book Value
$308.32
ROE
14.5%
ROA
6.1%
Div Yield
0.61%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 14,342,900,000 3,702,000,000 4,504,900,000 40,558,700,000 9,301,800,000 — 4,978,900,000
Dec 2024 14,202,000,000 3,990,700,000 4,412,600,000 37,759,400,000 8,405,800,000 — 4,420,500,000
Dec 2023 13,117,200,000 4,047,100,000 3,953,600,000 33,080,200,000 7,107,100,000 — 4,594,000,000
Dec 2022 12,172,900,000 4,738,900,000 4,338,400,000 29,214,500,000 6,550,500,000 — 5,014,900,000

TTM Snapshot

Revenues TTM
$3,720,700,000
NetIncome TTM
$1,340,600,000
OpCashFlow TTM
$0
Assets (Latest)
$37,759,400,000
Forward EPS
$53.77

Max Pain — expiry 2026-12-18

max pain strike: $710.00 · spot: $628.76 · call oi: 5,523 · put oi: 3,621
Expected Move to 2026-12-18: ±$123.45 (19.63%) — implied range $505.31 – $752.21 · ATM straddle on $630.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
TAK TAKEDA PHARMACEUTICAL CO LTD $50.05B $15.84 —
TKPHF TAKEDA PHARMACEUTICAL CO LTD $47.70B $30.19 —
SNY Sanofi $99.58B $41.60 —
SNYNF Sanofi $99.81B $83.39 —
GLAXF GSK plc $102.97B $25.70 —

News headlines (Yahoo Finance, 1h cache)

Will Priority-Reviewed Quarterly siRNA gMG Therapy Change Regeneron Pharmaceuticals' (REGN) Narrative?
2026-06-24 18:09 · Yahoo
Regeneron's Applications for gMG Drug Accepted by FDA and EMA
2026-06-23 18:24 · Yahoo
Are Biosimilars Becoming a Key Pillar of Amgen's Growth Story?
2026-06-23 13:50 · Yahoo
2 Underrated Weight Loss Stocks to Buy and Hold
2026-06-23 07:05 · Yahoo
Wells Fargo Maintains Overweight on AbbVie (ABBV), Sees Value in Apogee Acquisition
2026-06-23 04:41 · Yahoo
Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer
2026-06-22 22:14 · Yahoo
Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics—and Why the Stock Is Rising
2026-06-22 19:18 · Yahoo
AbbVie's $10.9 Billion Apogee Deal Joins a $200 Billion Pharma Spree
2026-06-22 18:59 · Yahoo
Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?
2026-06-22 13:35 · Yahoo
Questex’s DPHARM Announces Senior Leadership and Keynotes for the 16th Annual Conference
2026-06-22 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →